# US 2025/0152550 A1 · Lymph-targeting formulations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0152550 A1
- Document ID: US20250152550A1
- Status: Published application
- Kind: A1
- Application number: 18/250,509
- Filed: 2021-10-26
- Published: 2025-05-15
- Earliest claimed: 2021-10-26
- Assignees: Monash University; Auckland University Limited
- Applicants: Monash University; Auckland University
- Inventors: Natalie TREVASKIS; Christopher John PORTER; Given LEE; Sifel HAN; Anthony PHILLIPS; John WINDSOR; Jiwon HONG; Ian Kenneth STYLES; Zijun LU
- Web page: https://patentgrep.com/patent/US20250152550A1

## CPC

- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/0056: {Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals}
- A61K 9/107: Emulsions {; Emulsion preconcentrates; Micelles (composition of emulsions A61K47/00)}
- A61K 31/201: having one or two double bonds, e.g. oleic, linoleic acids
- A61K 31/365: Lactones
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to pharmaceutical formulations comprising a lipase inhibitor and long-chain fatty acids. The formulation enables the lipase inhibitor to be delivered to the intestinal lymph and are thereby useful in the treatment or prevention of diseases and conditions mediated by pancreatic lipase, such as acute pancreatitis and associated syndromes.

## Claims

### Claim 1

A pharmaceutical formulation comprising a lipase inhibitor and one or more long chain fatty acid.

### Claim 2 (depends on 1)

The pharmaceutical formulation according to claim 1, wherein the one or more long chain fatty acid is present in the formulation in an amount of at least 5 wt %.

### Claim 3 (depends on 1)

The pharmaceutical formulation according to claim 1, wherein the one or more long chain fatty acid is present in the formulation in an amount of at least 10 wt %.

### Claim 4 (depends on 1)

The pharmaceutical formulation according to claim 1, wherein the one or more long chain fatty acid has at least 14 carbon atoms.

### Claim 5 (depends on 1)

The pharmaceutical formulation according to claim 1, wherein the one or more long chain fatty is selected from the group consisting of myristic acid, pentadecanoic acid, palmitic acid, palmitoleic acid, heptadecanoic acid, stearic acid, oleic acid, linoleic acid, α-linoleic acid, linolenic acid, stearidonic acid, vaccenic acid, elaidic acid, linolelaidic acid, arachidonic acid, cervonic acid, eicosapentaenoic acid, paullinic acid, gondoic acid, erucic acid, nervonic acid, mead acid, docosatetraenoic acid, docosahexaenoic acid and combinations thereof.

### Claim 6 (depends on 5)

The pharmaceutical formulation according to claim 5, wherein the long chain fatty acid is oleic acid.

### Claim 7 (depends on 1)

The pharmaceutical formulation according to claim 1, wherein the lipase inhibitor is selected from the group consisting of cetilistat, lipstatin, orlistat, vibralactone, ebelactone, pancilin D, valilactone, esterastin and combinations thereof.

### Claim 8 (depends on 7)

The pharmaceutical formulation according to claim 7, wherein the lipase inhibitor is orlistat.

### Claim 9 (depends on 1)

The pharmaceutical formulation according to claim 1, further comprising at least one pharmaceutically acceptable carrier, diluent, surfactant or co-solvent.

### Claim 10 (depends on 1)

The pharmaceutical formulation according to claim 1, wherein the pharmaceutical formulation is a liquid formulation.

### Claim 11 (depends on 1)

The pharmaceutical formulation according to claim 1, wherein the pharmaceutical formulation is a veterinary formulation.

### Claim 12 (depends on 1)

A method of treating or preventing a disease or condition mediated by pancreatic lipase in a subject in need thereof comprising administering to the subject an effective amount of the pharmaceutical formulation according to claim 1.

### Claim 13 (depends on 1)

A method of treating or preventing acute pancreatitis or an associated syndrome of acute pancreatitis selected from systemic inflammatory response syndrome and/or multiple organ dysfunction syndrome in a subject in need thereof, comprising administering to the subject an effective amount of the pharmaceutical formulation according to claim 1.

### Claim 14 (depends on 12)

The method according to claim 12, wherein administration of the pharmaceutical formulation is enteral administration.

### Claim 15

A method of treating or preventing acute pancreatitis or an associated syndrome of acute pancreatitis selected from systemic inflammatory response syndrome and/or multiple organ dysfunction syndrome in a subject in need thereof, comprising enterally administering to the subject an effective amount of a lipase inhibitor and one or more long chain fatty acid, wherein the one or more long chain fatty acid is present in an amount sufficient to enhance or promote transport of the lipase inhibitor to the intestinal lymph.

### Claim 16

A method of treating or preventing acute pancreatitis or an associated syndrome of acute pancreatitis selected from systemic inflammatory response syndrome and/or multiple organ dysfunction syndrome in a subject in need thereof, comprising administering to the subject a formulation comprising an effective amount of a lipase inhibitor and one or more long chain fatty acid, wherein the formulation is a self-emulsifying drug delivery system and wherein the one or more long chain fatty acid is present in the formulation in an amount sufficient to enhance or promote transport of the lipase inhibitor to the intestinal lymph.

### Claim 17 (depends on 1)

The pharmaceutical formulation according to claim 1 for use in the treatment or prevention of acute pancreatitis and/or an associated syndrome of acute pancreatitis selected from systemic inflammatory response syndrome and/or multiple organ dysfunction syndrome in a subject in need thereof.

### Claim 18

A method for the treatment or prevention of acute pancreatitis and/or an associated syndrome of acute pancreatitis selected from systemic inflammatory response syndrome and/or multiple organ dysfunction syndrome in a subject in need thereof, the method comprising administering a therapeutically effective amount of a medicament comprising a lipase inhibitor, wherein the lipase inhibitor is formulated with one or more long chain fatty acid and wherein the one or more long chain fatty acid is present in an amount of at least 5 wt %.

### Claim 19

A method for the treatment or prevention of acute pancreatitis and/or an associated syndrome of acute pancreatitis selected from systemic inflammatory response syndrome and/or multiple organ dysfunction syndrome in a subject in need thereof, the method comprising administering a therapeutically effective amount of a medicament comprising a lipase inhibitor, wherein the lipase inhibitor is formulated with one or more long chain fatty acid and wherein the one or more long chain fatty acid is present in an amount sufficient to enhance or promote transport of the lipase inhibitor to the intestinal lymph when administered.

### Claim 20 (depends on 18)

The method according to claim 18, wherein the medicament is a self-emulsifying drug delivery system.

### Claim 21 (depends on 18)

The method according to claim 18, wherein the one or more long chain fatty acid has at least 14 carbon atoms.

### Claim 22 (depends on 18)

The method according to claim 18, wherein the long chain fatty acid is oleic acid.

### Claim 23 (depends on 18)

The method according to claim 18, wherein the lipase inhibitor is orlistat.

### Claim 24 (depends on 13)

The method according to claim 13, wherein administration of the pharmaceutical formulation is enteral administration.

### Claim 25 (depends on 19)

The method according to claim 19, wherein the medicament is a self-emulsifying drug delivery system.

### Claim 26 (depends on 19)

The method according to claim 19, wherein the one or more long chain fatty acid has at least 14 carbon atoms.

### Claim 27 (depends on 19)

The method according to claim 19, wherein the long chain fatty acid is oleic acid.

### Claim 28 (depends on 19)

The method according to claim 19, wherein the lipase inhibitor is orlistat.
